Imugene (ASX:IMU) said efficacy data from its phase 1b clinical trial evaluating the azer-cel drug candidate in patients with relapsed/refractory diffuse large B-cell lymphoma showed a best overall response rate of 79%, with 11 out of 14 patients showing a response to treatment, according to a Monday Australian bourse filing.
Two new patients became evaluable for responses, and both achieved a partial response, the filing said. The patients are being treated with azer-cel and interleukin 2.
The company is enrolling patients to the phase 1b azer-cel trial at 10 US sites, with up to six sites in Australia planned.
Imugene's shares jumped 10% in recent trading on Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。